Status:
UNKNOWN
AI Based Multi-modal Parameter of Peripheral Blood Cells (MMPBC) Predicts Survival Risk in Critically Ill Children
Lead Sponsor:
Zhujiang Hospital
Conditions:
Children
Eligibility:
All Genders
1-18 years
Brief Summary
This study aims to investigate whether an AI prediction model based on blood cell multi-modal data can achieve early warning of survival risk in critically ill children through a large-scale multi-cen...
Detailed Description
According to the definition of the United Nations Children's Fund (UNICEF), children are individuals between the ages of 0 and 18. Critically ill children are those who are admitted to the PICU or NIC...
Eligibility Criteria
Inclusion
- Children who were admitted to NICU and PICU from January 1, 2018, to March 31, 2023.
- Age \<18 years, gender not limited.
- Blood routine tests were performed using Mindray Medical's five-category blood cell analyzer (including BC6000, BC6000PLUS, BC6800PLUS, and BC7500 series), and the instrument or computer system retained relatively complete blood cell multi-modal data.
- Detailed clinical medical records related to this study can be obtained.
- Patients who were repeatedly admitted to NICU or PICU and had different conditions, causes, and outcomes each time were counted as new cases.
Exclusion
- Children with congenital immunodeficiency.
- Children with blood diseases, including iron-deficiency anemia, macrocytic anemia, hereditary spherocytosis, glucose-6-phosphate dehydrogenase deficiency, thalassemia, autoimmune hemolytic anemia, aplastic anemia, immune thrombocytopenia, acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, multiple myeloma, allergic purpura, myelodysplastic syndrome, etc.
- Children with genetic metabolic diseases, including galactosemia, mucopolysaccharidosis, glycogen storage disease, phenylketonuria, albinism, alkaptonuria, hypoxanthine-guanine phosphoribosyltransferase deficiency, chromhidrosis, Goucher disease, Tay-Sachs disease, etc.
- Children with chromosomal diseases, including Down syndrome, trisomy 18, etc.
- Children who received blood products within six months, including transfused blood components, human immunoglobulin, etc.
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT06034639
Start Date
March 1 2023
End Date
September 30 2023
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510000